Pasar al contenido principal

Lucas Moreno Martín-Retortillo

I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division  of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels

Instituciones de las que forman parte

Jefe de grupo
Cáncer y Enfermedades Hematológicas Infantiles
Vall Hebron Institut de Recerca
Director clínico
Oncología y Hematología Pediátrica
Hospital Infantil i Hospital de la Mujer

Lucas Moreno Martín-Retortillo

Instituciones de las que forman parte

Jefe de grupo
Cáncer y Enfermedades Hematológicas Infantiles
Vall Hebron Institut de Recerca
Director clínico
Oncología y Hematología Pediátrica
Hospital Infantil i Hospital de la Mujer

I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division  of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels

Dr. Lucas Moreno just moved to Barcelona to lead the Paediatric Oncology & Haematology Division at Vall d'Hebron Hospital. He has devoted his career to childhood cancer drug development. His main research interest is in neuroblastoma, one of the most aggressive forms of childhood cancer.
After returning from London where he worked at the Royal Marsden Hospital from 2008 to 2012, he created and led the Clinical Trials Unit at Hospital Niño Jesús (Madrid) that became a leading trials unit for paediatric drug development nationally and internationally.
He is a key opinion leader in neuroblastoma and drug development in Europe and works for international networks such as SIOPEN (siopen.net) and ITCC (itcc-consortium.org). He leads the BEACON-Neuroblastoma trial open in 10 European countries for relapsed & refractory neuroblastoma. He has been principal investigator of more than 30 clinical trials and has co-authored more than 60 international publications in the field.
He provides second opinion consultations for children and adolescents with relapsed/refractory cancers nationally and internationally to facilitate access to early clinical trials and novel agents.
He is a keen supporter of incorporating the patient/parents voice into research and clinical practice and has started several projects on quality of life, quality of care, late effects and patient reported outcomes. His favourite conference of the year is the Solving Kids’ Cancer Parent conference because of the excellent interaction between researchers, clinicians and parents.

Proyectos

BEACON-BIO: deep biological characterisation and development of biomarkers for relapsed neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Andrea Vilaplana Blanes, María Rosario Pérez- Torres Lobato
Entidad financiadora: European Science Foundation
Financiación: 104500
Referencia: BEACON-BIO_FKC_2021
Duración: 01/01/2022 - 30/09/2025

International integrated analysis to identify markers of poor survival in high-risk neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Andrea Vilaplana Blanes, Mariona Morell Daniel
Entidad financiadora: Solving Kids’ Cancer
Financiación: 131766.91
Referencia: SKC/AEFRM/2020/MORENO
Duración: 02/11/2020 - 01/11/2023

Quatsomes as a novel nanomaterial platform for nucleic acids delivery

IP: Miguel Segura Ginard
Colaboradores: Aroa Soriano Fernández, Lucas Moreno Martín-Retortillo
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 83600
Referencia: DTS20/00018
Duración: 01/01/2021 - 31/12/2022

Programa de fellowship para formación en Hematología y Oncología Pediátrica Hospital Vall d’Hebrón

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Genoveva Arqueros Sánchez
Entidad financiadora: Asociación padres niños oncológicos Aragón ASPANOA
Financiación: 30000
Referencia: ASPANOA/PROJ-BECA/2019/FERNANDEZ
Duración: 01/11/2019 - 30/04/2021

Noticias relacionadas

Esta gran participación es una muestra de la intensa actividad asistencial y de investigación del Campus dirigida a múltiples patologías infantiles.

El estudio observa el impacto de la COVID-19 en personas con trastornos poco frecuentes de los glóbulos rojos, identificando factores de riesgo para formas graves de la enfermedad

Gemma Viñals, patrona fundadora de Amics Joan Petit Nens amb Càncer Fundació, explica la colaboración con el VHIR para fomentar la investigación en cáncer infantil.

Profesionales relacionados

Carlos Frutos Gomez

Carlos Frutos Gomez

403
Dirección
Leer más
Gustavo Gimenez

Gustavo Gimenez

Investigador predoctoral
Enfermedades Infecciosas
Leer más
Andrés Bustos Mardones

Andrés Bustos Mardones

Investigador predoctoral
Cirugía Reconstructiva del Aparato Locomotor
Leer más
Margarita Gratacós Viñola

Margarita Gratacós Viñola

Sistema Nervioso Periférico
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.